HeartFlow, Inc. logo

HeartFlow, Inc. (HTFL)

Market Open
12 Jun, 13:43
NASDAQ (NMS) NASDAQ (NMS)
$
30. 75
+0.08
+0.2608%
$
2.47B Market Cap
- P/E Ratio
- Div Yield
47,519 Volume
- Eps
$ 30.67
Previous Close
Add Transaction
Day Range
30.65 31.35
Year Range
20.13 41.22
Want to track HTFL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

HTFL trading today higher at $30.75, an increase of 0.2608% from yesterday's close, completing a monthly increase of 3.8501% or $1.14. Over the past 12 months, HTFL stock gained 4.77%.
HTFL is not paying dividends to its shareholders.
The last earnings report, released on Mar 18, 2026, exceeded the consensus estimates by 0.1683%. On average, the company has surpassed earnings expectations by 0.1694%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

HTFL Chart

People also search for

Abivax SA ADR
$ 98.27
-2.5776%
Protagonist Therapeutics Inc.
$ 110.4
+0.5517%
State Street My2029 High Yield Corporate Bond ETF
$ 25.1
+0.4787%
Kymera Therapeutics Inc.
$ 83.65
+0.8317%
Rhythm Pharmaceuticals Inc.
$ 88.28
+0.713%
Heartflow Q1 Earnings Call Highlights

Heartflow Q1 Earnings Call Highlights

Heartflow NASDAQ: HTFL reported a sharply higher first-quarter revenue total and raised its full-year 2026 outlook, citing strength in its core FFRCT business, faster-than-expected adoption of its Plaque Analysis product and continued expansion of the coronary CT angiography, or CCTA, market.

Marketbeat | 4 weeks ago
HeartFlow, Inc. (HTFL) Q1 2026 Earnings Call Transcript

HeartFlow, Inc. (HTFL) Q1 2026 Earnings Call Transcript

HeartFlow, Inc. (HTFL) Q1 2026 Earnings Call Transcript

Seekingalpha | 4 weeks ago
HeartFlow: Getting Into The Flow

HeartFlow: Getting Into The Flow

HeartFlow delivered 40% sales growth in 2025, with revenue surpassing $176 million and strong Q4 momentum. 2026 guidance targets 25% revenue growth to $218–222 million, with gross margins rising to 80–81% and further mid-term upside to 85%. HearthFlow's AI-driven CAD diagnostic platform is gaining adoption, supported by FDA-cleared next-generation algorithms and a proprietary CT image database.

Seekingalpha | 2 months ago

HeartFlow, Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
Point72 Asset Management LP
Point72 Asset Management LP Point72 Asset Management LP
538,351 $15.47M $16.51M $1.04M 6.73%
JC
Joseph Castro Nuveen LLC
23,239 $677,417 $712,507.74 $35,090.74 5.18%
TC
Thomas Cagna Sandia Investment Management LP
15,917 $497,805.55 $488,174.39 -$9,631.16 -1.93%
BB
Brian Baylis Bell Investment Advisors Inc.
70 $2,040.5 $2,146.9 $106.4 5.21%
RO
Regan O'Neill Burkehill Global Management LP
65,000 $2.19M $2M -$185,250 -8.47%

HeartFlow, Inc. (HTFL) FAQ

What is the stock price today?

The current price is $30.75.

On which exchange is it traded?

HeartFlow, Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is HTFL.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 2.47B.

Has HeartFlow, Inc. ever had a stock split?

No, there has never been a stock split.

HeartFlow, Inc. Profile

Health Care Technology Industry
Healthcare Sector
John Farquhar CEO
NASDAQ (NMS) Exchange
42238D107 CUSIP
US Country
626 Employees
- Last Dividend
- Last Split
- IPO Date
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.

Contact Information

Address: 331 E. Evelyn Avenue
Phone: 650-241-1221